Special clinical interests in blood, genitourinary, prostate, urological, lymphoma, skin cancers and benign diseases suitable for radiotherapy.
Professor David Christie is based on the Gold Coast and attends GenesisCare treatment centres at Tugun and Southport. He also attends clinics at Pindara Private Hospital and in Northern NSW (Byron Bay and Tweed Hospital).
David qualified in Medicine from New Zealand’s University of Otago in 1987 and completed Radiation Oncology training in Sydney in 1995, at which time he moved to Queensland and commenced full-time practice. David has experience in treating all cancers that require radiotherapy but has a special interest in urological cancer and lymphoma, including brachytherapy for prostate cancer.
He is actively involved in research including national and international clinical trials. He has research and teaching roles with the University of New England as well as Bond and Griffith Universities.
Special clinical interests include urological cancer (including prostate brachytherapy), skin cancer (including wide field radiotherapy), benign diseases (including dupuytren’s disease), lymphoma and patients eligible for clinical trials.
Until recently, he was an editor for the only Radiation Oncology medical journal that is based in Australia, JMIRO.
Pindara Private Hospital
The Tweed Hospital
- Trans-Tasman Radiation Oncology Group (TROG)
- Journal of Medical Imaging & Radiation Oncology (former Editor)
- Bond University
- Griffith University
- University of New England
- The European Society for Radiation and Oncology (ESTRO)
- Professor Christie is an active contributor to several clinical trial organisations including TROG and has published over 150 publications which are accessible online.
- Andrew E. P., Christopher B. , Stephen S., Robert S., Walter J. C. J, David C, Bradley W, Peter F., Peter O’B., Lynda S. & on behalf of the National Dermatology Radiation Oncology Registry (NDROR) investigators and sites ‘Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancers’